LongevityResearch Phase

Klotho Peptide

Intravenous

Overview

Klotho is a transmembrane protein of approximately 1012 amino acids that exists in membrane-bound and secreted forms, with the soluble ectodomain functioning as a circulating factor. Klotho acts as a coreceptor for fibroblast growth factor 23 in phosphate metabolism and independently influences insulin signaling, oxidative stress, and cellular senescence pathways.

Mechanism of Action

Reduced klotho expression is associated with accelerated aging phenotypes in mice, while overexpression extends lifespan in rodent models. Therapeutic development focuses on peptide fragments or recombinant forms to replicate klotho's protective effects in age-related conditions..

Research Summary & Key Findings

Preclinical studies in rodents demonstrate that klotho administration improves cognition, attenuates kidney injury, and extends lifespan in some models. A small phase 1 trial evaluated recombinant klotho protein safety in healthy volunteers, confirming tolerability but not addressing longevity endpoints. No large-scale clinical trials have assessed klotho peptides for age-extension or healthspan outcomes in humans, leaving efficacy for longevity applications unproven.

Clinical Status

Research Phase

Klotho Peptide is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intravenous

Related Peptides in Longevity

Find a Provider

Find a verified provider who offers Klotho Peptide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Klotho Peptide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.